Degarelix
- Generic Name
- Degarelix
- Brand Names
- Firmagon, Degarelix Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C82H103ClN18O16
- CAS Number
- 214766-78-6
- Unique Ingredient Identifier
- SX0XJI3A11
- Background
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.
- Indication
Degaralix is used for the management of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2007-03-26
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 386
- Registration Number
- NCT00451958
- Locations
- 🇺🇸
South Orange County Medical Research Center, Laguna Hills, California, United States
🇺🇸Seattle Urology Research Center, Burien, Washington, United States
🇺🇸Urology Associates Research, Englewood, Colorado, United States
Exploratory Study Assessing Synchronisation of Egg Sacs With Degarelix
- Conditions
- Infertility, Female
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2011-06-02
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 85
- Registration Number
- NCT00434122
- Locations
- 🇪🇸
IVI-Madrid, Madrid, Spain
🇨🇿ISCARE IVF a.s., Prague, Czech Republic
🇪🇸IVI-Valencia, Valencia, Spain
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2012-12-19
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 620
- Registration Number
- NCT00295750
- Locations
- 🇺🇸
Office of Jeffrey Frankel, Seattle, Washington, United States
🇺🇸Western Clinical Research, Torrance, California, United States
🇺🇸Regional Urology, Shreveport, Louisiana, United States
Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2010-12-24
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 278
- Registration Number
- NCT00268892
- Locations
- 🇫🇷
Fédération d'Urologie et Néphrologie, BP69 Hôpital Pasteur, Nice, France
🇧🇪UZ Gasthuisberg Leuven, Leuven, Belgium
🇩🇪Gemeinschaftspraxis Dres Effert und Benedic, Aachen, Germany
Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2011-05-20
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT00245466
Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-05-20
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 131
- Registration Number
- NCT00215657
An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2015-04-01
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 137
- Registration Number
- NCT00215683
- Locations
- 🇩🇪
Vivantes Klinikum am Urban, Klinik für Urologie, Berlin, Germany
🇩🇪Urologische Universitätsklinikum, Klinikum Mannheim GmbH, Fakultät für Klinische Medizin Mannheim, Mannheim, Germany
🇭🇺Pez Aladar County Hospital, Dept. of Urology, Györ, Hungary
Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2011-05-23
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 82
- Registration Number
- NCT00117949
- Locations
- 🇺🇸
Urology Clinics of NorthTexas, PA, Dallas, Texas, United States
🇺🇸Western Clinical Research, Torrance, California, United States
🇺🇸Urology San Antonio Research, San Antonio, Texas, United States
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
- First Posted Date
- 2005-07-06
- Last Posted Date
- 2010-10-21
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 57
- Registration Number
- NCT00117286
- Locations
- 🇺🇸
Regional Urology, Shreveport, Louisiana, United States
🇺🇸Lawrenceville Urology, Lawrenceville, New Jersey, United States
🇨🇦The Male and Female Health and Research Centers, Barrie, Ontario, Canada
Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients
- First Posted Date
- 2005-07-06
- Last Posted Date
- 2011-05-23
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT00117312
- Locations
- 🇺🇸
Urology San Antonio Research, San Antonio, Texas, United States
🇺🇸South Orange County Medical Research Center, Laguna Woods,, California, United States
🇺🇸Western Clinical Research, Torrance, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.